PL1643983T3 - Sposoby hamowania przepuszczalności naczyń krwionośnych i apoptozy - Google Patents
Sposoby hamowania przepuszczalności naczyń krwionośnych i apoptozyInfo
- Publication number
- PL1643983T3 PL1643983T3 PL04776717T PL04776717T PL1643983T3 PL 1643983 T3 PL1643983 T3 PL 1643983T3 PL 04776717 T PL04776717 T PL 04776717T PL 04776717 T PL04776717 T PL 04776717T PL 1643983 T3 PL1643983 T3 PL 1643983T3
- Authority
- PL
- Poland
- Prior art keywords
- sphingosine
- methods
- vascular endothelial
- vascular permeability
- apoptosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48223403P | 2003-06-24 | 2003-06-24 | |
EP04776717A EP1643983B1 (en) | 2003-06-24 | 2004-06-18 | Methods of inhibiting vascular permeability and apoptosis |
PCT/US2004/019420 WO2005002559A2 (en) | 2003-06-24 | 2004-06-18 | Methods of inhibiting vascular permeability and apoptosis |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1643983T3 true PL1643983T3 (pl) | 2010-10-29 |
Family
ID=33563841
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL04776717T PL1643983T3 (pl) | 2003-06-24 | 2004-06-18 | Sposoby hamowania przepuszczalności naczyń krwionośnych i apoptozy |
Country Status (14)
Country | Link |
---|---|
US (3) | US7838562B2 (pl) |
EP (1) | EP1643983B1 (pl) |
JP (2) | JP2007523858A (pl) |
CN (2) | CN100431534C (pl) |
AT (1) | ATE466572T1 (pl) |
AU (1) | AU2004253473B2 (pl) |
BR (1) | BRPI0411831A (pl) |
CA (3) | CA2529318C (pl) |
DE (1) | DE602004027045D1 (pl) |
ES (1) | ES2342396T3 (pl) |
MX (1) | MXPA05014216A (pl) |
PL (1) | PL1643983T3 (pl) |
PT (1) | PT1643983E (pl) |
WO (1) | WO2005002559A2 (pl) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003094965A2 (en) | 2002-05-08 | 2003-11-20 | Neuronova Ab | Modulation of neural stem cells with s1p or lpa receptor agonists |
GB0329498D0 (en) | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
EP1845971A4 (en) * | 2005-01-21 | 2009-12-30 | Medvet Science Pty Ltd | METHOD FOR THE TREATMENT OF CELL DAMAGE |
KR100773765B1 (ko) | 2005-11-24 | 2007-11-12 | 재단법인서울대학교산학협력재단 | 개선된 스핑고신 유사체의 제조 방법 |
EP1905434A1 (en) * | 2006-09-26 | 2008-04-02 | Novartis AG | Organic compounds comprising an S1P receptor agonist and their therapeutic use |
CN102579387A (zh) * | 2006-09-26 | 2012-07-18 | 诺瓦提斯公司 | 包含s1p调节剂的药物组合物 |
CA2670116C (en) | 2006-11-22 | 2015-03-10 | Seaside Therapeutics, Llc | Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism |
EP3120833A1 (en) | 2007-10-12 | 2017-01-25 | Novartis Ag | Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators |
CN102464590B (zh) * | 2010-11-18 | 2013-10-23 | 中国科学院上海药物研究所 | 一类免疫调节剂及其制备方法和用途 |
ES2388273B1 (es) * | 2011-03-16 | 2013-10-01 | Consejo Superior De Investigaciones Científicas (Csic) | Uso de inhibidores de receptores de s1p para el tratamiento de la estenosis aórtica calcificada |
EP2831072B1 (en) | 2012-03-26 | 2017-04-19 | Arroyo BioSciences L.L.C. | Novel sphingosine 1-phosphate receptor antagonists |
WO2013181488A2 (en) * | 2012-06-01 | 2013-12-05 | The Ohio State University Research Foundation | Inhibition of leukemic stem cells by pp2a activating agents |
WO2014043334A1 (en) * | 2012-09-12 | 2014-03-20 | Oklahoma Medical Research Foundation | Modulation of podoplanin mediated platelet activation |
EP2990055B1 (en) * | 2013-04-26 | 2019-06-05 | Kyoto University | Composition comprising a sphingosine-1-phosphate receptor 1 agonist for inhibiting formation and/or enlargement of cerebral aneurysm or for shrinking it |
US10574647B2 (en) * | 2014-09-01 | 2020-02-25 | Passlogy Co., Ltd. | User authentication method and system for implementing same |
WO2016115092A1 (en) * | 2015-01-12 | 2016-07-21 | La Jolla Institute For Allergy And Immunology | Methods for targeting host vascular mechanism for therapeutic protection against hemorrhagic fever |
US10111841B2 (en) | 2015-06-19 | 2018-10-30 | University Of South Florida | Stabilization of alcohol intoxication-induced cardiovascular instability |
CN105395530A (zh) * | 2015-11-27 | 2016-03-16 | 天津医科大学总医院 | 芬戈莫德的新用途 |
CN105640928A (zh) * | 2016-02-26 | 2016-06-08 | 南京医科大学 | Fty720在制备预防与治疗缺血性脑卒药物中的应用 |
CN115120724A (zh) * | 2017-05-22 | 2022-09-30 | 北京蔚蓝之源医药科技有限公司 | 治疗再生障碍性贫血的方法和药物组合物 |
SG11202006255UA (en) * | 2018-02-02 | 2020-07-29 | Univ Kyoto | Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability |
EP3677259A1 (en) * | 2019-01-07 | 2020-07-08 | Mosaiques Diagnostics And Therapeutics AG | Use of arachidonyl trifluoromethyl ketone |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR960703597A (ko) * | 1993-07-23 | 1996-08-31 | 데이비드 엘 토메이 | 아폽토시스 및 관련 상태의 치료방법(methods of treating apoptosis and associated conditions) |
US5948820A (en) * | 1994-08-22 | 1999-09-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzene compound and pharmaceutical use thereof |
US6476004B1 (en) * | 1996-07-18 | 2002-11-05 | Mitsubishi Pharma Corporation | Pharmaceutical composition |
EP1006798A4 (en) * | 1996-09-05 | 2003-03-05 | Massachusetts Inst Technology | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS AND NEURODEGENERATIVE DISEASES |
GB9624038D0 (en) * | 1996-11-19 | 1997-01-08 | Sandoz Ltd | Organic compounds |
JPH1180026A (ja) * | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
JPH11246434A (ja) * | 1998-02-25 | 1999-09-14 | Sumitomo Pharmaceut Co Ltd | baxの低下及び/又はbcl−2の増加誘導剤 |
JP2002505868A (ja) * | 1998-03-09 | 2002-02-26 | スミスクライン・ビーチャム・コーポレイション | ヒトEDG−1cポリヌクレオチドおよびポリペプチドおよびその使用法 |
JP4627356B2 (ja) * | 1999-06-30 | 2011-02-09 | 松森 昭 | ウイルス性心筋炎の予防または治療薬剤 |
IL156304A0 (en) * | 2000-12-11 | 2004-01-04 | Tularik Inc | Cxcr3 antagonists |
US6471980B2 (en) * | 2000-12-22 | 2002-10-29 | Avantec Vascular Corporation | Intravascular delivery of mycophenolic acid |
EP1426762A4 (en) * | 2001-08-08 | 2007-05-09 | Chugai Pharmaceutical Co Ltd | DRUGS FOR CARDIAC DISEASES |
US20040058894A1 (en) * | 2002-01-18 | 2004-03-25 | Doherty George A. | Selective S1P1/Edg1 receptor agonists |
EP1469863A2 (en) * | 2002-01-18 | 2004-10-27 | Merck & Co., Inc. | Selective s1p1/edg1 receptor agonists |
GB0217152D0 (en) | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
-
2004
- 2004-06-18 DE DE602004027045T patent/DE602004027045D1/de active Active
- 2004-06-18 PL PL04776717T patent/PL1643983T3/pl unknown
- 2004-06-18 WO PCT/US2004/019420 patent/WO2005002559A2/en active Application Filing
- 2004-06-18 EP EP04776717A patent/EP1643983B1/en not_active Not-in-force
- 2004-06-18 US US10/562,305 patent/US7838562B2/en not_active Expired - Fee Related
- 2004-06-18 PT PT04776717T patent/PT1643983E/pt unknown
- 2004-06-18 CN CNB2004800175481A patent/CN100431534C/zh not_active Expired - Fee Related
- 2004-06-18 AT AT04776717T patent/ATE466572T1/de active
- 2004-06-18 MX MXPA05014216A patent/MXPA05014216A/es active IP Right Grant
- 2004-06-18 CN CN200810212366A patent/CN101518524A/zh active Pending
- 2004-06-18 CA CA2529318A patent/CA2529318C/en not_active Expired - Fee Related
- 2004-06-18 CA CA2778309A patent/CA2778309C/en not_active Expired - Fee Related
- 2004-06-18 JP JP2006517361A patent/JP2007523858A/ja not_active Withdrawn
- 2004-06-18 BR BRPI0411831-6A patent/BRPI0411831A/pt not_active IP Right Cessation
- 2004-06-18 CA CA2778126A patent/CA2778126A1/en not_active Abandoned
- 2004-06-18 ES ES04776717T patent/ES2342396T3/es active Active
- 2004-06-18 AU AU2004253473A patent/AU2004253473B2/en not_active Ceased
-
2010
- 2010-09-30 US US12/894,783 patent/US9101575B2/en not_active Expired - Fee Related
-
2014
- 2014-01-07 JP JP2014001034A patent/JP2014088421A/ja active Pending
-
2015
- 2015-06-18 US US14/743,352 patent/US20150283154A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE602004027045D1 (de) | 2010-06-17 |
US9101575B2 (en) | 2015-08-11 |
EP1643983B1 (en) | 2010-05-05 |
AU2004253473A1 (en) | 2005-01-13 |
MXPA05014216A (es) | 2006-03-13 |
US7838562B2 (en) | 2010-11-23 |
PT1643983E (pt) | 2010-06-18 |
WO2005002559A3 (en) | 2005-04-14 |
JP2007523858A (ja) | 2007-08-23 |
CA2778309A1 (en) | 2005-01-13 |
WO2005002559A2 (en) | 2005-01-13 |
ATE466572T1 (de) | 2010-05-15 |
JP2014088421A (ja) | 2014-05-15 |
CN101518524A (zh) | 2009-09-02 |
EP1643983A2 (en) | 2006-04-12 |
CA2529318C (en) | 2013-09-17 |
CN1826104A (zh) | 2006-08-30 |
CA2778126A1 (en) | 2005-01-13 |
ES2342396T3 (es) | 2010-07-06 |
CA2778309C (en) | 2014-12-02 |
US20080039530A1 (en) | 2008-02-14 |
BRPI0411831A (pt) | 2006-08-08 |
CA2529318A1 (en) | 2005-01-13 |
US20150283154A1 (en) | 2015-10-08 |
AU2004253473B2 (en) | 2010-03-04 |
CN100431534C (zh) | 2008-11-12 |
US20110015159A1 (en) | 2011-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL1643983T3 (pl) | Sposoby hamowania przepuszczalności naczyń krwionośnych i apoptozy | |
UA98629C2 (ru) | Соединения и способ модуляции киназ | |
TW200634006A (en) | Tetrahydroquinoline analogues as muscarinic agonists | |
MX2009008253A (es) | Derivados de 2-aminopiridina utiles como inhibidores de cinasa. | |
WO2008063842A3 (en) | Methods of treating neuropathic pain with agonists of ppar-gamma | |
MX2009006345A (es) | Compuestos utiles como inhibidores de proteina cinasa. | |
TW200639163A (en) | RAF inhibitor compounds and methods | |
MXPA05012678A (es) | Forma cristalina del agonista del receptor adrenergico beta2. | |
WO2008060907A3 (en) | Pyrrolo-pyridine kinase inhibitors | |
EA200970447A1 (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
UA111933C2 (uk) | Піролопіридини як інгібітори кінази | |
EP2111107A4 (en) | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | |
WO2007098474A8 (en) | Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as s1p receptor agonists | |
WO2004010987A3 (en) | Use of s1p receptor agonists in heart diseases | |
TNSN08140A1 (pl) | ||
MY159955A (en) | Certain chemical entities, compositions and methods | |
EA201000130A1 (ru) | Бициклические гетероарильные соединения и их применение в качестве ингибиторов киназы | |
MX2009001062A (es) | Agonistas de ep2. | |
WO2007100640A3 (en) | Growth hormone receptor antagonist cancer treatment | |
HK1139705A1 (en) | Growth medium for c. histolyticum without ingredients of mamalian sources | |
EA201100255A1 (ru) | 5-алкинилпиримидины | |
RU2014124430A (ru) | Средство для лечения фиброза кишечника | |
AU2010236734A8 (en) | 5-HT4 receptor agonist compounds for treatment of cognitive disorders | |
EA201100254A1 (ru) | Новые соединения | |
WO2007109288A3 (en) | Enantiomerically pure r-etifoxine, pharmaceutical compositions thereof and methods of their use |